Wells Fargo Sees Amphastar Pharmaceuticals, Inc.’s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth

Core Insights - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is recognized as one of the 12 most promising small-cap stocks by Wall Street analysts [1][2] - Wells Fargo has reduced its price target for AMPH from $34 to $30 while maintaining an Overweight rating, citing pressure on the stock due to lowered sales projections despite recent product approvals [3] - The FDA approved AMPH's Abbreviated New Drug Application for Ipratropium Bromide HFA Inhalation Aerosol, which is expected to enhance the company's market position in the respiratory medication sector [4][6] Company Developments - The FDA's approval of Ipratropium Bromide HFA Inhalation Aerosol grants AMPH 180 days of generic exclusivity, as it is the first ANDA applicant to receive a Paragraph IV certification [5] - This approval is a significant regulatory milestone that supports the company's Q4 2025 earnings report and positions it for increased market share [6] - AMPH specializes in developing, manufacturing, and marketing injectable, inhalation, and intranasal medications, focusing on critical care needs and drug delivery innovations [7] Market Outlook - Wells Fargo emphasizes that the performance of AMP-007 will be crucial for achieving mid-to high-single-digit revenue growth in the future [3][10]